Literature DB >> 10347102

The relative role of the Child-Pugh classification and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis.

W R Kim1, J J Poterucha, R H Wiesner, N F LaRusso, K D Lindor, J Petz, T M Therneau, M Malinchoc, E R Dickson.   

Abstract

The Child-Pugh classification is a simple, convenient prognostic measure in patients with liver cirrhosis. We investigated the relative role of the Child-Pugh classification and the Mayo model in the assessment of survival in patients with primary sclerosing cholangitis (PSC). Of the 173 patients described in the original Mayo PSC natural history model, 147 patients had sufficient information in the medical record to allow computation of the Child-Pugh score. We used our most recent modification of the Mayo model to compute the risk score, based on patient's age, serum levels of bilirubin, albumin, and aspartate aminotransferase and history of variceal bleeding. Using the risk score (R), patients were divided into the low- (R < 0), intermediate- (0 </= R < 2), and high-risk (R >/= 2) groups. Kaplan-Meier estimates and proportional hazards analysis were used to evaluate the two prognostic models. Although there was a statistically significant correlation between the Child-Pugh and Mayo risk scores, two-thirds of the patients had a Child-Pugh score of 5 or 6 and a relatively wide range of risk scores (-1.1-4.3). The probability of survival for 7 years in patients in the low-, intermediate-, and high-risk groups was 92%, 74%, and 40% for Child-Pugh class A (n = 96) and 100%, 62%, and 28% for Child-Pugh class B patients (n = 44), respectively. There were only a small number (n = 7) of Child-Pugh class C patients. In our age-adjusted multivariate analysis, each unit increase in the Mayo risk score was associated with a 2.5-fold increase in the risk of death (95% confidence interval: 1.8-3.4, P <.01), whereas Child-Pugh classification had no significant impact on survival (Child-Pugh B vs. A: risk ratio = 1.1 [95% confidence interval: 0.6-2.0]; Child-Pugh C versus A: risk ratio = 0.6 [95% confidence interval: 0. 2-1.8]). In contrast to the Child-Pugh classification, which was developed for advanced liver cirrhosis, the Mayo model provides valid survival information, particularly in patients early in the course of PSC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347102     DOI: 10.1002/hep.510290607

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

Review 1.  Current therapies and clinical controversies in the management of primary sclerosing cholangitis.

Authors:  R T Prall; K D Lindor; R H Wiesner; N F LaRusso
Journal:  Curr Gastroenterol Rep       Date:  2000-04

2.  Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis.

Authors:  Patrick G Northup; Ryan C Wanamaker; Vanessa D Lee; Reid B Adams; Carl L Berg
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  Primary sclerosing cholangitis treated by endoscopic biliary dilation: review and long-term follow-up evaluation.

Authors:  G Kenneth Johnson; Kia Saeian; Joseph E Geenen
Journal:  Curr Gastroenterol Rep       Date:  2006-04

Review 4.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 5.  A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

Authors:  Elizabeth C Goode; Simon M Rushbrook
Journal:  Ther Adv Chronic Dis       Date:  2016-01       Impact factor: 5.091

6.  Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.

Authors:  Andrea N Edginton; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study.

Authors:  Paul Angulo; Roberta A Jorgensen; Kris V Kowdley; Keith D Lindor
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

8.  The impact of liver metastasis on mortality in patients initially diagnosed with locally advanced or resectable pancreatic cancer.

Authors:  Chigusa Nakahashi; Tatsuya Oda; Taira Kinoshita; Takanori Ueda; Masaru Konishi; Toshio Nakagohri; Kazuto Inoue; Junji Furuse; Atsushi Ochiai; Nobuhiro Ohkohchi
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 9.  Endoscopy in the management of primary sclerosing cholangitis.

Authors:  Mark McLoughlin; Robert Enns
Journal:  Curr Gastroenterol Rep       Date:  2008-04

Review 10.  Recurrence of cholestatic liver disease after living donor liver transplantation.

Authors:  Sumihito Tamura; Yasuhiko Sugawara; Junichi Kaneko; Junichi Togashi; Yuichi Matsui; Noriyo Yamashiki; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.